Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wheeler

Showing results (1131-1140 of 1,154) with videos related to

Pageof 116
Sort By:
Vaccine|June 7, 2006
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Luisa L Villa, Kevin A Ault, Anna R Giuliano, et al.
American Journal of Human Genetics|November 26, 2018
MACF1 Mutations Encoding Highly Conserved Zinc-Binding Residues of the GAR Domain Cause Defects in Neuronal Migration and Axon GuidanceWilliam B Dobyns, Kimberly A Aldinger, Gisele E Ishak, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
The Lancet. Infectious Diseases|July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyCosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Nature|November 12, 2025
GREGoR: accelerating genomics for rare diseasesMoez Dawood, Ben Heavner, Marsha M Wheeler, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
Vaccine|October 22, 2008
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineElmar A Joura, Susanne K Kjaer, Cosette M Wheeler, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 yearsDarron R Brown, Susanne K Kjaer, Kristján Sigurdsson, et al.
Pageof 116

Showing results (1131-1140 of 1,154) with videos related to

Sort By:
Pageof 116
Vaccine|June 7, 2006
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Luisa L Villa, Kevin A Ault, Anna R Giuliano, et al.
American Journal of Human Genetics|November 26, 2018
MACF1 Mutations Encoding Highly Conserved Zinc-Binding Residues of the GAR Domain Cause Defects in Neuronal Migration and Axon GuidanceWilliam B Dobyns, Kimberly A Aldinger, Gisele E Ishak, et al.
BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.
The Lancet. Infectious Diseases|July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyCosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Human Vaccines|October 27, 2009
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infectionSven-Eric Olsson, Susanne K Kjaer, Kristján Sigurdsson, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 yearsCosette M Wheeler, Susanne K Kjaer, Kristján Sigurdsson, et al.
Nature|November 12, 2025
GREGoR: accelerating genomics for rare diseasesMoez Dawood, Ben Heavner, Marsha M Wheeler, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
Vaccine|October 22, 2008
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineElmar A Joura, Susanne K Kjaer, Cosette M Wheeler, et al.
The Journal of Infectious Diseases|February 25, 2009
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 yearsDarron R Brown, Susanne K Kjaer, Kristján Sigurdsson, et al.
Pageof 116